144) Further phylogenetic analyses of M. |
145) tial and important DNA molecular data for further phylogenetic analysis for not only |
146) tial and important DNA molecular data for further phylogenetic analysis for not only |
147) tial and important DNA molecular data for further phylogenetic analysis for not only |
148) tial and important DNA molecular data for further phylogenetic analysis for not only |
149) tial and important DNA molecular data for further phylogenetic analysis for not only |
150) tial and important DNA molecular data for further phylogenetic analysis for not only |
151) We further explored associations between gamm |
152) re and daily ambulance demand in 2036 was further explored by including and excludin |
153) trategy is very interesting and should be further explored for clinical applications |
154) CCA; HP(G/A)11] of β-globin gene LCR, we further explored the differential behavior |
155) ategies focussing on resilience should be further explored. |
156) ential role of rs13347C > T in AML was further explored. |
157) n all included parts and the result, upon further development and validation, may se |
158) Findings underscore the need for further development in psychological thera |
159) The aim of the study was a systematical further development of targeted approaches |
160) suggest some research directions for the further development of this field of model |
161) structs open intriguing possibilities for further development. |
162) The results thereby provide further support for the acknowledged 'elus |
163) inally developed IPQ-RH scale and provide further support for the theoretically deve |
164) We believe that our findings give further support of gamma oscillations as a |
165) Conclusions : Our results further support the linkage results for th |
166) ow-up to study RIMVs' hemodynamics and to further support the reliability of the ret |
167) Further validation in large population-bas |
168) during cellular adherence and warrant its further validation as a potential pharmaco |
169) s for survival in GC patients but require further validation by larger studies. |
170) With further validation of the sensitivity of d |
171) retrospective design used in this study, further validation of this finding is warr |
172) ficit (TPED) was 34° on day 1, improving further by day 7 to 42°. |
173) Here, we investigate further by examining multiple brands of co |
174) This is supported further by finding correlations between di |
175) al vaccine candidates and these validated further by methods such as RNA interferenc |
176) hepatocyte cells in the Sub-G0/G1 state, further confirmed by Annexin V binding ass |
|